clonoSEQ is now covered by Medicare for MCL patients.
It is the first Medicare-reimbursed MRD test for patients with MCL and is clinically available as a CLIA-validated LDT.
For more information about incorporating clonoSEQ into your clinical practice for MCL patients, click here.
Electronic Medical Records (EMR) Integration
Integrating clonoSEQ ordering and reporting
Adaptive offers EMR integration for most platforms, allowing providers to electronically order clonoSEQ and view results in line with other relevant treatment information.
Benefits of EMR Integration
Leverage integration for a seamless ordering experience and streamlined clinical decision-making.
For Patients
Test results are shared directly with patients via your EMR’s portal. Integrated results are available sooner.
For Clinics
Save time and improve order accuracy. Streamline order placement and view results alongside relevant treatment information.
For Laboratories
Quicker turnaround times and a more efficient pathology workflow. EMR integration with Adaptive reduces administrative overhead.
Epic Aura Integration
If you currently place lab orders in your Epic system, this integration is available for no additional cost
- Our partnership enables all Epic customers to easily integrate clonoSEQ orders and results within their existing workflows.
- Epic Aura integration takes 8-12 weeks with a clear project plan and experienced project team.
Leverage discrete data to make informed clinical decisions
Data Accessibility:
We are committed to ensuring critical information for patient care is available for decision making. That’s why we send all our results to Epic’s Care Everywhere network and Carequality.
Getting Started:
Reach out to Adaptive:
Fill out our Product Inquiry Form to get started or email our team: emrsupport@adaptivebiotech.com
Connect with an Integration Specialist:
One of our Integration Specialists will reach out to gather additional information as needed.
Project definition:
The Adaptive team will coordinate with you to outline project goals, participants, and timelines.
For Additional Support:
Adaptive Clinical Services Team
Call 1-888-552-8988, opt. 1 from 5:30 am to 5 pm PT, Monday through Friday, or email clinicalservices@adaptivebiotech.
Laboratory Shipping Address
Adaptive Biotechnologies
Attention: CLIA Clinical Laboratory
1165 Eastlake Avenue E
Seattle, WA 98109
Intake Hours
Monday–Saturday
8 am to 5 pm PT
Laboratory Licenses
View our CAP accreditation and our CLIA license.
Biological specimens can be received and accessioned on the days and times above.
Samples cannot currently be received on Sundays.
Epic, Aura, and Care Everywhere are trademarks of Epic Systems Corporation
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.